Abstract

Background: Heart failure with reduced ejection fraction (HFrEF) post-acute ST-segment elevation myocardial infarction (STEMI) significantly impacts morbidity and mortality. Identifying predictive biomarkers for HFrEF can aid in early intervention and improve outcomes. Methods: This prospective cohort study involved 50 patients post-STEMI, analyzing the predictive value of baseline serum iron levels for HFrEF development over six months. Statistical analyses included logistic regression to adjust for potential confounders. Results: The incidence of HFrEF at six months was 40%. Patients who developed HFrEF had significantly lower baseline serum iron levels compared to those who did not (58.4 µg/dL vs. 70.1 µg/dL, P=0.033). Multivariate analysis revealed that each 10 µg/dL decrease in serum iron was associated with a 25% increase in the odds of developing HFrEF (aOR 1.25, 95% CI 1.07-1.45, P=0.005). The sensitivity and specificity of serum iron levels in predicting HFrEF were 60% and 66.7%, respectively. Conclusion: Serum iron levels at admission post-STEMI are a significant predictor of HFrEF development within six months. These findings advocate for the inclusion of serum iron level assessment in the post-STEMI evaluation process, highlighting the potential for early therapeutic interventions.

Description